Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20312711 | 0.81 | IKBKB (0.35) | GRM5CYP1A2IKBKBSMN1; SMN2ALDH1A1 | |
| SCHEMBL17706530 | 0.81 | THRB (0.35) | THRBCA9GRM5HPGDALOX15 | |
| SCHEMBL14458093 | 0.80 | THRB (0.38) | THRBCA9GRM5HPGDALOX15 | |
| SCHEMBL595464 | 0.80 | ALDH1A1 (0.41) | THRBCA9HPGDALOX15CES2 | |
| SCHEMBL1585112 | 0.79 | KMT2A (0.36) | GRM5PKMCYP2C9CYP2C19IKBKB | |
| SCHEMBL30409470 | 0.79 | PTGS2 (0.33) | IKBKBGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL31134721 | 0.79 | KMT2A (0.36) | GRM5PKMCYP2C9CYP2C19IKBKB | |
| SCHEMBL1855234 | 0.79 | PTGS2 (0.33) | IKBKBGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL28393342 | 0.78 | KMT2A (0.37) | THRBHPGDALOX15CES2GALR3 | |
| SCHEMBL12647208 | 0.78 | GRM5 (0.53) | THRBGRM5HPGDALOX15PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255042-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC (KR) | 2020-12-30 | — | — | EP | disclosed |
| EP-3255042-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC (KR) | 2020-12-30 | — | — | EP | disclosed |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2020-06-18 | — | — | US | disclosed |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2020-04-07 | — | — | US | disclosed |
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2019-05-09 | — | — | US | disclosed |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2018-09-27 | — | — | US | disclosed |
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
| WO-2017132538-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
| WO-2016126085-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 비욘드바이오주식회사 | 2016-08-11 | — | — | WO | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | THRB 2083/4885CA9 801/4885GRM5 3329/4885 |
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | THRB 4215/4885CA9 1615/4885GRM5 1047/4885 |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | THRB 4215/4885CA9 1615/4885GRM5 1047/4885 |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK3, CDK1 | THRB 3541/4885CA9 1804/4885GRM5 924/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | THRB 2083/4885CA9 801/4885GRM5 3329/4885 |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | THRB 4215/4885CA9 1615/4885GRM5 1047/4885 |
| US-20170217980-A1 | AMLEXANOX ANALOGS | GPR119, GLP1R, IRS1 | THRB 768/4885CA9 4828/4885GRM5 2608/4885 |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | THRB 4215/4885CA9 1615/4885GRM5 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.